
Myelodysplastic syndrome is a group of cancers that prevents hematopoietic stem cells from developing into healthy blood cells. Without enough healthy blood cells, people risk developing dangerous illnesses such as anaemia, frequent infections, and uncontrollable bleeding. Some patients with MDS may develop acute myeloid leukaemia (AML).
Myelodysplastic Syndrome (MDS) should be treated as soon as possible to prevent it from progressing to acute myeloid leukaemia (AML), relieve symptoms such as fatigue and anaemia, and improve general health.
Early intervention enhances the efficacy of chemotherapy and stem cell transplants, improving outcomes. It also helps to reduce life-threatening complications such as infections and bleeding, which improves the prognosis and survival rates.
Therefore, timely treatment is critical for effectively controlling MDS and giving patients a better long-term outlook.
People with myelodysplastic syndromes may not exhibit signs and symptoms at first.
Myelodysplastic syndromes could cause:
The World Health Organisation classifies myelodysplastic syndromes into subcategories based on the kind of blood cells involved (red cells, white cells, and platelets).
The myelodysplastic syndrome has several subtypes, including:
Causes
Risk Factors
The following factors can raise your risk of myelodysplastic syndromes:
Complications
Myelodysplastic syndromes can have the following complications:
Chemotherapy: Healthcare practitioners may administer the same chemotherapy used to treat AML. It uses medications to eliminate cancer cells and inhibit tumour growth.
Cost Start From USD 1500 - USD 3500Explore Options
Immunosuppressive therapy: Providers may utilise this medication for some MDS subtypes. Immunosuppressive medication reduces overactive immune systems, reducing the need for transfusions.
Cost Start From USD 15000 - USD 50000Explore Options
Bone Marrow Transplant: A bone marrow transplant, also known as a stem cell transplant, is the only treatment that can cure myelodysplastic disorders.
Rehabilitation for Hepatocellular Carcinoma (HCC) is an essential component of the rehabilitation process and enhances quality of life, particularly following surgery, liver transplantation, or other treatments. Here are some indispensable rehabilitation choices for HCC patients:
MediGence can assist and guide you in selecting the best physician and medical facility for your care.
Treatment for myelodysplastic syndromes may include medications such as:









Kuala Lumpur, Malaysia
Sunway Medical Centre has initiated a comprehensive expansion plan close to its current hospital facility to enhance its ability to provide services to the global market. The new Cancer Radiosurgery Center and Nuclear Medicine Center, which will also house additional Centers of Excellence like the Digestive Health Center and Dialysis Center, marked the completion of Tower C's first phase in October 2016.

Kuala Lumpur, Malaysia
Prince Court is a private medical facility in the center of Kuala Lumpur that has 277 individual beds. Our dedication is to provide you with the best treatment possible from the time you arrive until you depart, healthier and happier. We are well-known for our top-notch facilities, cutting-edge technology, and friendly customer service.

Kuala Lumpur, Malaysia
Subang Jaya Medical Center is renowned for pioneering radiation oncology treatments and infrastructure in Malaysia. The hospital also has a state-of-the-art Cancer Radiosurgery Centre (CRC), which is fully furnished with the latest medical technology for cancer detection, monitoring, and treatment.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are the reasons for selecting Malaysia for Myelodysplastic syndrome (MDS) treatment.
The life expectancy of individuals with Myelodysplastic Syndromes (MDS) in Malaysia varies according to age, health status, and sickness risk classification. The range of the median survival time is several months to over ten years. However, individual health and the severity of the condition can affect survival chances. Patients should consult with medical professionals to find out their specific prognosis and available treatments.
MDS and leukaemia involve the bone marrow and blood cells, but MDS is a disorder in which the bone marrow generates abnormal cells. In contrast, leukaemia is characterised by the fast, uncontrolled proliferation of defective blood cells. MDS is sometimes thought to be a precursor to leukaemia since it can progress to acute myeloid leukaemia (AML) in some circumstances; however, the two illnesses are separate.
While most cases of MDS are not inherited, specific gene changes can raise the chance of getting the disease. In rare situations, MDS can be inherited as part of a genetic condition, such as Fanconi anaemia. You should speak with a genetic counsellor if you have a family history of blood diseases.
In Malaysia, myelodysplastic syndromes (MDS) are indeed curable. The nation boasts cutting-edge medical facilities and skilled oncologists who provide therapies like stem cell transplants, chemotherapy, and tailored medications.
Adopting cutting-edge technology and individualised treatment in Malaysian medical facilities increases the likelihood that MDS patients will receive successful treatment and achieve better results.
For high-risk MDS and cases that progress to acute myeloid leukaemia, chemotherapy is frequently utilised.
Chemotherapy restores normal blood cell production by eliminating aberrant cells from the bone marrow.
Chemotherapy for MDS is offered in large cancer hospitals in Malaysia, where doctors create individualised treatment regimens.
With the right care, many MDS patients can lead comparatively normal lives. However, symptoms such as exhaustion, recurring infections, and the requirement for blood transfusions can significantly impact a person's life. Following treatment with stem cell transplants, medications, and blood transfusions, patients can typically maintain a high quality of life.
Myelodysplastic syndromes (MDS) are the subject of ongoing study in Malaysia, which is aided by organisations such as the Institute for Medical Study and the Clinical Research Centre. Globally, new therapies are promising, including the oral hypomethylating medication combo decitabine/cedazuridine and the telomerase inhibitor imetelstat. Although the availability of these medicines is still rising, there is promise for improved MDS care due to Malaysia's increasing participation in clinical trials.